摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(甲氧基甲基)哌嗪 | 247061-64-9

中文名称
1-(甲氧基甲基)哌嗪
中文别名
——
英文名称
(methoxymethyl)piperazin
英文别名
1-(Methoxymethyl)piperazine
1-(甲氧基甲基)哌嗪化学式
CAS
247061-64-9
化学式
C6H14N2O
mdl
——
分子量
130.19
InChiKey
KPEXIQJQIAIMMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    24.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:8ea6248a14b75741869e45d6abc22d52
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(甲氧基甲基)哌嗪 、 alkaline earth salt of/the/ methylsulfuric acid 以 甲醇 为溶剂, 以43%的产率得到双(甲氧基甲基)哌嗪
    参考文献:
    名称:
    Cyanomethylamines and azidomethylamines: new general methods of the synthesis and transformations
    摘要:
    Simple and efficient methods have been developed to obtain cyanomethylamines and azidomethylamines using reactions of methoxymethylamines with TMSCN and TMSN3, respectively. In the case of dimethylformamide dimethylacetal, only one MeO group was substituted with CN, and an unexpected direction of the subsequent azidation was found. Adducts of azidomethylamines with DMAD were studied, and the base-catalyzed isomerization of symmetric triazoles into non-symmetric ones was revealed.
    DOI:
    10.1016/j.mencom.2009.09.018
点击查看最新优质反应信息

文献信息

  • NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:EP3305789A1
    公开(公告)日:2018-04-11
    The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.
    本发明提供了一种具有抗病毒活性的新型化合物,特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示: 其中A3为CR3A、CR3A R3B、N或NR3C;R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基,或取代或未取代的非芳香碳环烷基;R3C为氢原子、取代或未取代的烷基,或取代或未取代的非芳香碳环烷基;环T1为取代或未取代的含氮非芳香杂环;R1为氢原子、卤素、氰基,或取代或未取代的烷基;R2分别为取代或未取代的烷基或类似物;n为1或2;R3为取代或未取代的芳香碳环烷基或类似物;R4为氢原子或羧基保护基。
  • NOVEL OLEFIN DERIVATIVE
    申请人:Matsumura Akira
    公开号:US20150246938A1
    公开(公告)日:2015-09-03
    The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.
    本发明的目的是提供具有ACC2抑制活性的新型化合物。此外,本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物: 其中R1是取代或未取代的芳基等, R2各自独立为氢,取代或未取代的烷基等, R3各自独立为氢,取代或未取代的烷基等, n是0到3的整数, R12是氢,取代或未取代的烷基等, 环A是芳香碳环或芳香杂环, R9是取代或未取代的烷基,取代或未取代的烯基等, m是0到4的整数, R4和R5各自独立为氢,取代或未取代的烷基等, R6是取代或未取代的烷基,取代或未取代的烯基等, R13是氢,取代或未取代的烷基等, X5是键等, R7是氢或取代或未取代的烷基, R8是取代或未取代的烷基碳酰,取代或未取代的烯基碳酰等。
  • [EN] INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS<br/>[FR] MODULATEURS A BASE DE DERIVES INDOLIQUES DES RECEPTEURS NUCLEAIRES DES HORMONES STEROIDES
    申请人:LILLY CO ELI
    公开号:WO2004067529A1
    公开(公告)日:2004-08-12
    The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
    本发明提供了一种I式化合物或其药学上可接受的盐,包括I式化合物的有效量与适当载体、稀释剂或赋形剂组合而成的药物组合物,以及治疗生理紊乱的方法,特别是充血性心脏病,包括向患者施用I式化合物的有效量。
  • [EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1
    申请人:SHIONOGI & CO
    公开号:WO2014065434A1
    公开(公告)日:2014-05-01
    The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid beta proteins. A compound of the formula (I):wherein X is -C(R3a)(R3b)-, -C(R3a)(R3b)-C(R3c)(R3d)- or -C(R3a)=C(R3c)-, R1 is substituted or unsubstituted alkyl or the like,R2a, R2b, R3a, R3b, R3c and R3d are each independently hydrogen, halogen or the like, R4 is hydrogen or halogen,Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种化合物,具有抑制淀粉样蛋白β产生的作用,特别是抑制BACE1的作用,并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物:其中X为-C(R3a)(R3b)-,-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-,R1为取代或未取代的烷基或类似物,R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物,R4为氢或卤素,环B为取代或未取代的碳环或取代或未取代的杂环,或其药学上可接受的盐。
  • HIV REPLICATION INHIBITOR
    申请人:Shionogi & Co., Ltd.
    公开号:US20140249306A1
    公开(公告)日:2014-09-04
    The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein, a broken line means the presence or absence of a bond; R 1 is substituted or unsubstituted alkyl etc., R 2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R 3 is a substituted or unsubstituted aromatic carbocyclic group; R 4 is a hydrogen atom etc.; R 5 is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R 6 is substituted or unsubstituted alkyl; R 7 is —Z—R 71 etc.; Z is —NR 72 —CO— etc.; R 71 is substituted or unsubstituted alkyl etc.; R 72 is a hydrogen atom etc.
    本发明提供了一种具有抗病毒作用的新化合物,特别是具有抑制HIV复制作用的化合物,以及一种药物组合物,特别是一种抗HIV药物。其中,虚线表示键的存在或不存在;R1是取代或未取代的烷基等,R2是取代或未取代的烷氧基等;n为1或2;R3是取代或未取代的芳香环烷基;R4是氢原子等;R5是取代或未取代的芳香环烷基等;Y是单键等;R6是取代或未取代的烷基;R7是—Z—R71等;Z是—NR72—CO—等;R71是取代或未取代的烷基等;R72是氢原子等。
查看更多